Read more about the NTE programme on Teva's website here. In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along ...

After reinvigorating a decades-old schizophrenia drug in an innovative long-acting treatment option, Teva is looking to ...

The case is Teva Branded Pharmaceutical Products R&D Inc v. Amneal Pharmaceuticals of New York LLC, U.S. Court of Appeals for the Federal Circuit, No. 24-1936.

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...

Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...

Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $21.24 which represents a decrease of $-0.06 or -0.28% from the prior close of $21.3. The stock opened at $21.4 and ...

Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets. Catalyst stock ...

On December 20, 2024, the US Court of Appeals for the Federal Circuit released its opinion in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal ...

Sanofi and Teva Pharmaceuticals have reported that the ... a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only.